NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Sep. 2014 was $633 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2014 was $2,435 Mil.
This is the expense the company spent on research and development.
Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Sep. 2014 was 655.273796398 (Dec. 2013 ) + 586.884031123 (Mar. 2014 ) + 560.507464319 (Jun. 2014 ) + 632.650587808 (Sep. 2014 ) = $2,435 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Novo Nordisk A/S Annual Data
|Research & Development||791||808||1,119||1,669||1,425||1,540||1,703||1,703||1,916||2,156|
Novo Nordisk A/S Quarterly Data
|Research & Development||432||452||565||462||480||501||655||587||561||633|